Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing

• Published in: International journal of molecular sciences Vol. 23; no. 2; p. 583
• Main Authors: Sadeghi, Hosna Mohammad, Adeli, Ida, Calina, Daniela, Docea, Anca Oana, Mousavi, Taraneh, Daniali, Marzieh, Nikfar, Shekoufeh, Tsatsakis, Aristidis, Abdollahi, Mohammad
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.01.2022; MDPI
• Subjects: Disease Management; Drug Repositioning; Epigenetics; Female; Hormones; Humans; Hyperandrogenism; Insulin Resistance; Kinases; Polycystic ovary syndrome; Polycystic Ovary Syndrome - drug therapy; Polycystic Ovary Syndrome - etiology; Polycystic Ovary Syndrome - metabolism; Review; United States > US; molecular mechanisms; hyperandrogenism; management; insulin resistance; repurposing drugs; polycystic ovary syndrome
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23020583

Polycystic ovary syndrome (PCOS) is an endocrine-gynecology disorder affecting many women of childbearing age. Although a part of the involved mechanism in PCOS occurrence is discovered, the exact etiology and pathophysiology are not comprehensively understood yet. We searched PubMed for PCOS pathogenesis and management in this article and ClinicalTrials.gov for information on repurposed medications. All responsible factors behind PCOS were thoroughly evaluated. Furthermore, the complete information on PCOS commonly prescribed and repurposed medications is summarized through tables. Epigenetics, environmental toxicants, stress, diet as external factors, insulin resistance, hyperandrogenism, inflammation, oxidative stress, and obesity as internal factors were investigated. Lifestyle modifications and complementary and alternative medicines are preferred first-line therapy in many cases. Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucose-like peptide-1 receptor agonists, mucolytic agents, and some supplements have supporting data for being repurposed in PCOS. Since there are few completed clinical trials with a low population and mostly without results on PCOS repurposed medications, it would be helpful to do further research and run well-designed clinical trials on this subject. Moreover, understanding more about PCOS would be beneficial to find new medications implying the effect via the novel discovered routes.